| 3 min read
As therapies grow more complex, inactive ingredient innovation is needed to improve drug impact and access.
| 2 min read
New study uses simulations and machine learning to identify a single, high-impact interaction within a viral fusion protein, highlighting a potential new target for antiviral drug development.
| 9 min read
Rather than replacing radiologists, AI is working alongside them to catch cancers earlier and improve screening efficiency.News
| 4 min read
Billion-dollar partnerships, Phase 1 wins, AI regulatory tools, and more led the news this week.
| 7 min read
They’re approved by the FDA and Medicare and inching closer to widespread adoption nationally. But how good are they at detecting colorectal cancer?
| 5 min read
From virtual control groups to brain organoids, new approach methodologies are transforming how drugs and cosmetics are tested for safety.
| 3 min read
Automation may help address longstanding bottlenecks in CAR-T and TCR-T development
| 5 min read
Early clinical data suggest that intratumoral delivery may halt tumor activity and support bone regeneration in metastatic breast cancer.
| 6 min read
A clinical trial showed that Rhapsido can safely and effectively treat chronic spontaneous urticaria; its developer Novartis hopes that’s just the start.
| 5 min read
Emerging optogenetic, gene, and cell therapies are moving beyond single-gene treatments, offering hope for a broader range of patients with retinitis pigmentosa.
| 3 min read
Novo Nordisk’s Phase 3 trials revealed that oral semaglutide failed to slow the progression of disease.
| 4 min read
FDA updates, pharma tariff agreements, gene editing deals, and more led the news this week.
